Nano-biomaterials in cancer therapy: Advances in targeting and overcoming cancer stem cell resistance
Multifunctional nanoplatforms hold substantial potential to overcome CSC-driven resistance, improve therapeutic selectivity, and reduce recurrence. However, rigorous optimization and clinical validation are essential before these technologies can be integrated into routine oncology. This review advances understanding by outlining the intersection of CSC biology and nanomedicine, emphasizing translational pathways for CSC-targeted cancer therapy.
Authors
- Parviz Abdolmaleki (ORCID: https://orcid.org/0000-0003-4131-2919)
- Behnam Hajipour‐Verdom (ORCID: https://orcid.org/0000-0002-9799-6849)
- Fatemeh Rahimzadeh (ORCID: https://orcid.org/0000-0003-0323-4489)
- Marzieh Dehghani (ORCID: https://orcid.org/0009-0001-5121-7037)
Institutions
- The University of Sydney (AU)
- Tarbiat Modares University (IR)
- Motamed Cancer Institute (IR)
Publication Details
- Journal
- ADMET & DMPK
- Published
- 2025-10-24
- DOI
- https://doi.org/10.5599/admet.3007
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- Iran National Science Foundation
- Tarbiat Modares University